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The objective of the present study was to validate the use of intralesional injection of interleukin-2 (IL-2) in patients with skin and soft-
tissue melanoma metastases. A total of 24 patients with AJCC stage III or IV melanoma and single or multiple skin and soft-tissue
metastases were included. Interleukin-2 injections were administered intralesionally into the total number of cutaneous and soft-tissue
metastases accessible from the skin, 2–3 times weekly, over 1–57 weeks. Single doses varied from 0.6 to 6 10
6IU, depending on
lesion size. The clinical response was monitored by sonography and confirmed by histopathology; response evaluation was confined
to the intralesionally treated tumours. Complete response (CR) of the treated metastases was achieved in 15 patients (62.5%), the
longest remission lasting 38 months to date. In five patients, partial response (PR) was achieved (21%) and in another three patients,
progressive disease was observed (one patient not assessable). A total of 245 metastases were treated with CR in 209 (85%), and PR
in 21 (6%). The therapy was generally well tolerated; the observed adverse events were mainly of grade 1–2 severity.
Immunohistochemical studies showed the tumour cells undergoing apoptosis and revealed a mixed character of the inflammatory
infiltrate. The unusual high CR rate in metastatic melanoma of 62.5% and the limited toxicity suggest that treatment of skin and soft-
tissue melanoma metastases with intralesional injection of IL-2 may be a safe and effective alternative to conventional therapies. The
optimal dosage and duration of this therapy still remain to be defined in larger prospective multicentre trials.
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To date, there is no recommended standard therapy for advanced
melanoma with skin and soft-tissue metastases. Although a
number of therapies, such as surgery, limb perfusion, systemic
chemo- or immunochemotherapy, and radiotherapy are currently
in use for this situation, management of advanced melanoma with
skin and soft-tissue metastases can be a major challenge,
particularly in cases of rapidly progressive disease, multiple
recurrences, and extensive previous therapy. Surgery is usually
restricted to situations with limited disease extension and becomes
less indicated with increasing number of recurrences. Systemic
chemo- or immunochemotherapies as possible alternatives are also
usually of only limited benefit, as skin and soft-tissue metastases
often respond poorly and these therapies are commonly associated
with severe side effects. Radiotherapy is generally considered as a
last resort for advanced melanoma and commonly has only a
temporary effect (Pitts and Maloney, 2000; Reeves and Coit, 2000;
Walsh et al, 2000).
Intralesional therapy modalities generally lack the severe side
effects of systemic therapies and, provided sufficient efficacy, can
be desirable alternatives to surgery, systemic therapy, or radio-
therapy. The therapeutic value of several intralesionally adminis-
tered cytostatic agents and cytokines, such as fotemustine
(Schallreuter et al, 1991), bleomycin (Glass et al, 1996; Heller
et al, 1998), cisplatin (Burris et al, 1998), interferon-alfa (von
Wussow et al, 1988), interferon-beta (Fierlbeck et al, 1992; Umeda
et al, 1998; Cornejo et al, 2000), and GM-CSF (Vaquerano et al,
1999) has been investigated with varying outcome. However, none
of these therapies has yet been shown to be a convincing
alternative to conventional therapies.
Interleukin-2 (IL-2) was described to be efficient in treating
cutaneous and soft-tissue metastases administered intravenously
(Phan et al, 2001) and administered intralesionally in a few cases
(Gutwald et al, 1994a,b). Therefore, we addressed the question of
whether intralesional IL-2 is effective in treating soft-tissue
metastasis when other therapeutic measures like surgery, limb
perfusion, radiotherapy, or chemotherapy had failed to control the
disease. Intralesional IL-2 treatment was performed with the aim of
achieving a complete regression of all cutaneous and soft-tissue
metastases accessible from the skin.
Here, we present the results of a study investigating the
feasibility, efficacy, and safety of intralesionally injected IL-2 in
24 melanoma patients with skin and soft-tissue metastases.
MATERIALS AND METHODS
Patients
Between November 1998 and April 2002, 24 patients, 14 females
and 10 males, aged 19–83 years, with AJCC stage III–IV
melanoma, were included in this study. The study protocol was
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lapproved by our institutional ethic committee, and patients gave
their consent after being informed of the investigational nature of
the study. Patients were required to have a life expectancy of 3
months or longer, and no evidence of infection. Patients were not
eligible for enrolment into the study if they had grade 3 or 4
cardiac, pulmonary, or CNS disease.
The general characteristics of the patients are summarised in
Table 1. At the time of study inclusion, 16 patients had stage III
disease, 15 patients had cutaneous or subcutaneous intransit
metastases, and one patient had recurring regional lymph node
metastases. In all of them, surgical excisions had been previously
performed, and in some of them radiotherapy (two patients) and
limb perfusions (three patients) had been additionally applied.
Eight patients were included in stage IV disease, two of them with
exclusively cutaneous/subcutaneous metastasis, and six with
cutaneous metastasis in combination with visceral metastasis. In
the 18 patients (16 with stage III disease and two with stage IV
disease) with locoregional or exclusively cutaneous metastasis, the
total number of soft-tissue metastases accessible from the skin
have been included in the intratumoral therapy with IL-2. The six
patients with simultaneous visceral metastases had developed their
cutaneous/subcutaneous metastases under systemic chemother-
apy. They were included because they had the feeling of a stigma
by their visible metastases. All patients had received previous
therapies for melanoma (summarised in Table 2): all 24 patients
had undergone multiple surgical procedures, six had received
systemic chemotherapy with vindesine, another six had received
systemic immunochemotherapy with dacarbazine and IFN-alpha
(IFN-a), and one had received systemic immunotherapy with IFN-
a. Four patients had been treated with localised radiotherapy, and
four patients had undergone limb perfusion with dactinomycin
and melphalan. None of the patients had received previous IL-2
therapy.
Study design
Patients were exclusively treated on an outpatient basis at the
Department of Dermatology, University of Tuebingen, Germany.
For the preparation of stock solution, 18MIU recombinant human
IL-2 (Proleukin
s, Chiron, Ratingen, Germany) was dissolved in
6ml glucose (5%) prepared with albumin (0.2%) solution. The
stock solution was injected intralesionally, single doses varied
from 0.6–6MIU (0.2–2.0ml), depending on the lesion size (see
Table 3). The maximum daily dose was 12MIU IL-2.
Injections were given intralesionally. Treatment was initially
given to the largest metastases until the maximum dose was
reached. For deep soft-tissue metastases, sonography was used to
guide injections. In the further course, additional smaller
metastases were likewise treated. In larger lesions several
injections have been applied. Up to 20 small cutaneous lesions
have been treated simultaneously. The treatment schedule was 2–3
times weekly for 1–12 weeks. In most of the patients, treatment
duration was between 2 and 4 weeks, and the average of injections
per lesion was 10 times.
Most patients tolerated the IL-2 injections well, although in
single cases the injections were painful. Systemic symptoms have
been exclusively treated by metamizole sodium, a common
nonsteroidal antipyretic and antiphlogistic. The incidence of
adverse events associated with IL-2 treatment was recorded and
adverse events were graded according to the WHO criteria.
Assessment of response and survival probability
The response to treatment was assessed by using the standard
criteria of response. The response evaluation has been performed
on the basis on an intent-to-treat analysis. Complete response (CR)
was defined as disappearance of all clinical evidence of the
intralesionally treated tumour. For deep soft-tissue metastases,
sonography was used to monitor the clinical response. Addition-
ally, in selected cases biopsies were taken after the completion of
therapy for histopathological confirmation of response. Lack of
any tumour growth after its clinical regression over a period of at
least 6 months was the criterion to classify the result of treatment
as CR. Partial response (PR) was defined as a greater than 50%
decrease in the sum of product of perpendicular diameters.
Survival curves have been calculated according to the method of
Kaplan and Meier separately for the disease stages III and IV
taking the diagnosis of the respective disease stage as the start
point for the calculation.
Histopathology and confocal laser scanning microscopy
(CLSM)
To confirm complete regression of the tumour by histopathology,
biopsies were taken after treatment. Sections of the formalin-fixed
and paraffin-embedded tissue were stained with haematoxylin and
eosin for routine histopathology. To obtain information on the
Table 1 Patient characteristics
Total no. of patients 24
Gender
Male 10 (42%)
Female 14 (58%)
Age (years)
Median 59.2
Range 19–83
Stage of disease
Metastatic 24 (100%)
American Joint
Committee on Cancer
Stage III 16 (67%)
Stage IV 8 (33%)
Sites of metastases
Cutaneous 2 (8%)
Soft tissue 22 (92%)
Visceral 4 (17%)
Table 2 Prior treatment
Type of treatment No. (%)
Total no. of patients 24 (100%)
Surgery 24 (100%)
Immunotherapy (IFN-a) 1 (4%)
Chemotherapy (vindesin) 6 (25%)
Chemotharapy (Dacarbazine) 2 (8%)
Immunochemotherapy (Dacarbazine+IFN-a) 6 (25%)
Local radiotherapy 4 (17%)
Limb perfusion (melphalan+dactinomycin) 4 (17%)
Table 3 Treatment regimen
Lesion size maxim.
diameter (mm)
Single
dose MIU
Stock
solution (ml)
Duration of
treatment
(weeks)
o5 0.6 0.2 2
45 1.2 0.4 3
410 3.0 1.0 4
420 6.0 2.0 4
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lmechanism of tumour regression, biopsies taken during treatment
were studied using immunofluorescence stainings. Vertical paraf-
fin sections (3mm thick) were pretreated and labelled with
anticaspase 3 (rabbit anti-human/mouse-caspase 3, R&D Systems,
Wiesbaden, Germany), anti-MART-1/Melan A (monoclonal anti-
MelanA, Inno Genex, San Ramon, CA, USA), anti-CD3 (rabbit
anti-human-CD3, Linaris, Wertheim, Germany), and anti-CD56
(monoclonal anti-CD56, Novocastra, Dossenheim, Germany).
Secondary antibodies were labelled with Cy2, Cy3, and Cy5
(Molecular Probes, Leiden, Netherlands). Nuclei were stained with
YOPRO (green) or TOPRO (blue) (Molecular Probes, Leiden,
Netherlands). The sections were analysed with a confocal laser
scanning microscope (Leica TCS SP, Leica Microsystems, Ben-
sheim, Germany).
RESULTS
Response
Of the 24 patients, 23 included in the study were assessable for
response. One patient with two treated metastases (patient no. 22
in Table 4) was not evaluable for assessing the regression of
intralesionally treated lesions, since the injected lesions could not
be followed for at least 4 weeks post-treatment due to rapid disease
progression and death after 4 weeks.
CR of all intralesionally treated lesions was achieved in 15
patients, the longest remission lasting 38 months to date. In two
patients, CR of all except one lesion was achieved, one lesion in
each of these patients was classified as not assessable: (1) in patient
no. 1 (Table 4) disease progression occurred with visceral
metastases, and IL-2 therapy was changed to systemic immuno-
chemotherapy with temozolomide and IFN-a before the response
of this single lesions could be assessed. (2) In patient no. 9
(Table 4), a single lesion was surgically excised before completion
of IL-2 therapy.
Three patients were classified as PR: in patient no. 4 (Table 4), a
definite initial response to IL-2 therapy was seen on sonography.
However, when the patient showed disease progression with
visceral metastases, IL-2 therapy was changed to systemic
immunochemotherapy, but no biopsies of the treated lesions were
obtained prior to initiation of systemic therapy to confirm a
possible CR. In the second patient classified as partial response
(no. 13, Table 4), we had initially classified all 15 lesions as CR. Yet,
in one biopsy of a treated lesion, beneath areas of total regression,
a small area of vital micrometastasis was seen on histopathology.
We therefore reclassified all 15 lesions as PR. The third patient (no.
23 in Table 4) had shown response on ultrasound, unfortunately he
developed an abscess at the treated lesion and the region was
treated surgically. Therefore, response was classified only as
partial.
Altogether, we treated a total of 245 skin and soft-tissue mela-
noma metastases in 24 patients. We found CR in 209 metastases
(85%) and PR in 21 metastases (6%), seven metastases showed
progression (3%) and eight metastases (3%) were not assessable.
None of the patients with CR developed any local recurrence. We
did not observe any systemic response to the local IL-2 treatment,
which means we observed no clear regression of any other
metastasis simultaneously present, but not intralesionally treated.
Histopathology and CLSM
Biopsies were performed in selected cases. The histology of
biopsies taken after the end of therapy showed a necrosis of
the tumour tissue and an intra- and peritumorous lymphocytic
Table 4 Treatment details, response, and subsequent course of disease
Patient
Age
(years) Sex Stage
Number of
treated
metastases
IL-2 dose
(MIU)
Weeks of
treatment
Histopathologic
response
evaluation
Local
response
Subsequent course
of systemic disease,
systemic therapy
Current
status
1 38 F III 3 281 16 Not done 2 CR, 1 NA VM (4 M)/T+IFN DE
2 62 F III 17 397.5 57 Done 17 CR Stable AL, DF
3 69 F III 5 447 53 Done 5 CR VM (16 M)/IFN DE
4 61 M III 4 61 12 Not done 4 PR VM (3 M)/T+IFN DE
5 74 M III 2 99 8 Not done 2 CR VM (4 M)/T+IFN AL, DF
6 59 F III 3 18 2 Not done 3 CR Stable AL, DF
7 83 F III 1 18 4 Not done 1 CR VM (6 M) AL
8 65 M IV 50 79 8 Done 50 CR VM (2 M)/T+IFN DE
9 63 M III 11 287 18 Done 10 CR, 1 NA VM (5 M)/IFN AL
10 58 M III 1 8 5 Done 1 CR Stable AL, DF
11 52 F IV* 3 115 4 Done 3 CR Further progression/V DE
12 30 F III 3 103 7 Not done 3 CR Further progression/
BOLD
DE
13 35 F IV* 15 119.2 12 Done 15 PR Further progression/
D+IFN
DE
14 68 M IV 45 91 4 Done 45 CR Stable AL, DF
15 60 F IV* 7 118 20 Not done 4 NA, 3 PD Further progression/T AL
16 66 F III 5 18 2 Not done 5 CR Stable AL, DF
17 64 M III 1 15.5 2 Done 1 CR Stable AL, DF
18 51 F IV* 4 88 8 Not done 1 PR, 3 PD Further progression/
T+IFN
DE
19 64 F III 2 175 8 Done 1 CR, 1 PD VM (7 M)/S+HP AL, DF
20 78 M III 20 38.5 12 Done 20 CR VM (2 M) AL
21 72 F III 20 10.5 5 Not done 20 CR Stable AL, DF
22 19 M IV* 2 9 1 Not done 2 NA Further progression/R DE
23 59 M IV* 1 54 3 Not done 1 PR Further progression/T AL
24 70 F III 20 67.5 4 Done 20 CR Stable AL, LM
Stage: IV*¼visceral metastases; IL-2 dose (MIU): cumulative dose expressed in 10
6 international units; Response: CR¼complete response, PR¼partial response, NA¼not
assessable, PD¼progression; Subsequent course of systemic disease: VM (4 M)¼progression to stage IV with visceral metastasis (4 months after commencement of IL-2 therapy),
D¼dacarbazine, IFN¼interferon-alfa, T¼temozolomide, V¼vindesine, BOLD¼polychemotherapy (BOLD regimen), S¼surgery, HP¼hyperthermic limb perfusion,
R¼radio therapy; Current status (July 2000): Al¼alive, DF¼disease free, LM¼local metastatsis, VM¼visceral metastasis, DE¼dead.
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linfiltrate. No vital tumour cells could be detected and necrotic
tumour cells appeared as cell shadows. Furthermore, monocytes,
macrophages, and melanophages were seen (Figure 1A and B).
Only in one single case vital tumour cells forming micrometastasis
were found.
Analysis using immunofluorescence techniques and the CLSM
revealed a positive staining for caspase 3 in 30–50% of tumour
cells already after 1 week of treatment (Figure 2A). These apoptotic
cells increasingly lost their reactivity for anti-Melan A staining.
Vital tumour cells were strongly positive for Melan A in most
cases. The mononuclear infiltrate was predominantly composed of
CD3-postive T cells, and only in some areas CD56-positive, CD3-
negative NK cells can be found (Figure 2B). NK cells constitute
only a minor proportion of the infiltrate.
Treatment toxicity
Intralesional IL-2 therapy caused a dose-dependent inflammatory
reaction at the site of injection with local swelling and erythema,
which completely resolved within days of discontinuation of
therapy. On sonography, this IL-2-induced inflammatory reaction
could be corroborated as a change in the lesion signal from low-
intensity to a slightly higher intensity. Clinically, the inflammatory
reaction induced a selective necrosis of the tumour tissue that
generally did not affect the surrounding normal tissue. In a few
cases (three) with high cumulative IL-2 doses and severe
inflammatory reaction, the necrosis exceeded the tumour tissue
and resulted in a sterile ulceration of the skin, which healed within
weeks of therapy completion.
The incidences of the observed adverse events are given in
Table 5. The therapy was generally well tolerated. The most
common adverse event was local erythema and slight local
swelling, which have been observed nearly regularly. Pain due to
the injections was also frequent (n¼16; 67%). The majority of
patients described fever (n¼14; 58%) and flu-like symptoms with
chills and night sweats (n¼14; 58%) that were easily controlled
with the use of NSAIDs (metamizole, acetaminophen). Fatigue and
nausea or emesis were also common, but usually mild and of short
duration. Mild abdominal pain and gastritis-like symptoms,
diarrhoea, muscle cramps, and tachycardia were observed in
single patients. With the exception of one patient, no grade 3 or 4
adverse events were associated with this therapy. This patient
(patient no. 13 in Table 4) experienced severe headache, classified
as a grade 3 adverse event, which developed within hours of IL-2
injection on one occasion. The patient had advanced disease with
extensive visceral and intra-cerebral metastases that may have
exacerbated the headache.
Subsequent course of disease
We did not see any recurrences in the treated cutaneous lesions
previously responding with CR. However, following intralesional
IL-2 therapy, nine of 16 patients in stage III disease progressed to
stage IV disease with visceral metastases. The time span between
the start of IL-2 therapy and disease progression was 2–16 months.
An overview of the subsequent clinical course, treatment, and
current status is given in Table 4. Survival curves according to the
method of Kaplan and Meier showed that in stage III disease, the
2-year survival rate was 100% and the 5-year survival rate was
63%, and in stage IV disease the 1-year survival rate was 63% and
the 2-year survival rate was 33% (Figures 3 and 4).
DISCUSSION
The results of our pilot study showed that intralesional injection of
IL-2 is an effective treatment for soft-tissue melanoma metastases
accessible from the skin. The observation of 62.5% CR rate and
83.5% overall response rate is unexpectedly high, and suggests that
this new treatment modality may be an interesting alternative to
Figure 1 Histology of biopsies taken after the completion of therapy. Complete necrosis of the tumour tissue and a mainly peritumoral lymphocytic
infiltrate (A) haematoxylin and eosin; original magnification  40. No viable tumour cells are recognisable; necrotic tumour cells appear as cell shadows.
Furthermore, monocytes and macrophages are seen. (B) Haematoxylin and eosin; original magnification  200.
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lexisting therapies. The clinical situation of each patient in this
study was challenging at the time of study inclusion, as most
patients had rapidly progressive disease or had suffered multiple
recurrences. All patients had received extensive previous therapy,
including surgery, systemic immuno/chemotherapy, limb perfu-
sion, and radiotherapy, and in the use of surgery had been
exhausted.
Intralesional application of antitumorous agents appears as an
appealing therapeutic concept, as very high concentrations of the
applied agent can be reached within the tumour, which may be
essential to attain the desired therapeutic effect. When given
systemically, the concentration of IL-2 within the tumour is several
magnitudes lower than under intralesional therapy. However, IL-2
administered intravenously was observed in a subgroup of 28
patients with subcutaneous and cutaneous melanoma metastases
respectable 53% responder (Phan et al, 2001). The resounding
effect of intralesional IL-2, which we found in this study was not
observed with systemic IL-2 therapy, and is therefore most likely a
result of the high intratumoral IL-2 concentration. Furthermore,
with intralesional therapy the cumulative IL-2 doses are generally
lower than with systemic therapy and as a result, the severe side
effects of systemic IL-2 therapy (Keilholz et al, 1998; Legha et al,
1998; Eton et al, 2000; Phan et al, 2001) were not observed in our
study.
A number of reports of treatment of melanoma metastases with
intralesional application of agents with direct or mediated
antitumoral effect have been published. Several cytostatic agents,
including fotemustine (Schallreuter et al, 1991), bleomycin (Glass
et al, 1996; Heller et al, 1998), and cisplatin (Burris et al, 1998)
have been used intralesionally, with varying results. As immune
mechanisms have been shown to play a significant role in the
pathogenesis and clinical course of melanoma (reviewed in Curiel-
Lewandrowski and Demierre, 2000), a number of reports have
addressed the treatment of melanoma metastases with intralesion-
ally injected immunemodulatory cytokines, including interferon-
Figure 2 Immunoflourescence staining for Melan A/Mart-1 (green) and caspase-3 (red) detects vital and apoptotic tumour cells. Nuclei stained blue.
Images were taken using a CLSM at 630-fold magnification (A). Confocal laser scanning microscopy image of the inflammatory infiltrate: CD3-positive T-
lymphocytes stained blue, CD56-positive/CD3-negative NK cells stained red, nuclei green, final magnification 630-fold (B). Most NK cells are found in small
groups near to a capillary (arrow).
Table 5 Adverse events during intralesional IL-2 therapy, graded
according to WHO criteria
Adverse event WHO grade I II III IV
Local erythema and slight swelling 24 (100%) 0 0 0
Fever 1 (4%) 13 (54%) 0 0
Flu-like symptoms 8 (33) 6 (25%) 0 0
Pain 7 (29) 9 (38%) 0 0
Fatigue 11 (46%) 0 0 0
Nausea/vomiting 8 (33%) 2 (8%) 0 0
Stomach pain 4 (17%) 0 0 0
Diarrhoea 2 (8%) 1 (4%) 0 0
Headache 2 (8%) 0 1 (4%) 0
Muscle cramp 1 (4%) 0 0 0
Tachykardia 1 (4%) 0 0 0
Number of patients and incidence rate.
1.0
0.8
0.6
0.4
0.2
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Figure 3 Survival of patients treated with intralesional administered IL-2.
Time of diagnosis of stage III respective stage IV disease was taken as the
start point for survival curves.
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lalpha (von Wussow et al, 1988), interferon-beta (Fierlbeck et al,
1992; Umeda et al, 1998; Cornejo et al, 2000), and GM-CSF
(Vaquerano et al, 1999). However, with none of these cytokines
satisfactory results were achieved. The successful use of intrale-
sional IL-2 in the treatment of malignant tumours, including
melanoma metastases (Gutwald et al, 1994a,b), squamous cell
carcinoma (Whiteside et al, 1993), metastatic eccrine poroma
(Dummer et al, 1992), malignant haemangioendothelioma (Inad-
omi et al, 1992), carcinoma erysipeloides (Hamamoto et al, 2001),
and in newer times with PEG-IL-2 on basal cell carcinoma has only
been published in single case reports (Kaplan and Moy, 2000). Our
study is the first to evaluate the feasibility, efficacy, and safety of
intralesional IL-2 in a phase II trial in 24 patients.
The most likely mechanism of tumour regression is the creation
of lymphokine-activated killer cells (LAK cells) by IL-2 and
subsequent destruction of the tumour by the ability of LAK cells to
lyse tumour cells or to induce apoptosis directly. LAK cells are
derived from either NK cells or from CD8-positive T-cells (Abbas
et al, 1994). They have been shown to play a critical role in the
antitumoral immune response in vitro and in vivo (Ferlazzo et al,
1997; Chikamatsu et al, 1999; Hajkova et al, 1999; de Gast et al,
2000). Indeed, on the histology of biopsies taken from IL-2-treated
metastases, we found a dense intra- and peritumoral lymphocytic
infiltrate surrounding and infiltrating the areas of necrotic tumour
cells. Using CLSM, we could show that tumour cells undergo
apoptosis and that the mononuclear infiltrate mainly consists of T
cells and to a minor extent of NK cells. So in the setting of
intratumoral IL-2 treatment, LAK cells are supposed to be
activated T cells inducing apoptosis in tumour cells. Further
studies on the mechanism of tumour regression induced by local
treatment with IL-2 are needed.
It is difficult to judge whether the intralesional IL-2 treatment is
suitable to contribute to prolongation of survival, as survival was
not an end point of the study protocol. The survival curves
calculated for this patient collective seem to be favourable, but do
not allow definitive conclusions. Most importantly, they do not
hint at any kind of life-shortening effects of the intratumoral IL-2
therapy.
In conclusion, our study has documented the feasibility of
intralesional IL-2 therapy in melanoma patients with skin and soft-
tissue metastases. The overall response rate of 62.5% and its
limited toxicity suggest that this new therapy may be a suitable
alternative to systemic dacarbazine treatment in this particular
subset of melanoma patients. The optimal dosage and duration of
this therapy still remain to be defined in larger prospective
multicentre trials. An interesting question is whether intralesional
IL-2 therapy may also be effective in the treatment of metastases of
other solid tumours.
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